Answers are grounded in this paper and cite their sources.
TRPM4 plays a crucial role in cardiac electrophysiology, offering a potential therapeutic target for arrhythmias and ischaemia-reperfusion injury, and its mutations are implicated in conduction blocks and Brugada syndrome.
TRPM4 forms a non-selective cation channel activated by internal Ca(2+). Its functional expression was demonstrated in cardiomyocytes of several mammalian species including humans, but the channel is also present in many other tissues. The recent characterization of the TRPM4 inhibitor 9-phenanthrol, and the availability of transgenic mice have helped to clarify the role of TRPM4 in cardiac electrical activity, including diastolic depolarization from the sino-atrial node cells in mouse, rat, and rabbit, as well as action potential duration in mouse cardiomyocytes. In rat and mouse, pharmacological inhibition of TRPM4 prevents cardiac ischaemia-reperfusion injuries and decreases the occurrence of arrhythmias. Several studies have identified TRPM4 mutations in patients with inherited cardiac diseases including conduction blocks and Brugada syndrome. This review identifies TRPM4 as a significant actor in cardiac electrophysiology.
No takes yet. Share an insight, caveat, or question.
Guinamard et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: